Lung Innate Immunity and Microbiome After Tuberculosis Exposure
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorUniversity of Oxford
About this trial
To characterise the innate pulmonary immune response and respiratory microbiome after recent exposure to M.tb and to evaluate how differences determine the outcome of M.tb exposure
Eligibility criteria
Qualifiers
Adults aged 18-65 years
Resident in or near London or Oxford for the duration of the study period
Provide written informed consent
Willing to allow the investigators to review the volunteer's review NHS care record, medical history, blood results and radiographs.
Disqualifiers
Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment or during the trial follow up period.
History of anaphylaxis or any allergy likely to be exacerbated by any essential study procedure
History of currently poorly controlled of airways disease (including asthma), current cancer (except BCC of the skin or CIS of the cervix), bleeding disorder, or drug or alcohol abuse
Any significant autoimmune conditions or immunodeficiency (including HIV)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
50 Participants
are grouped into 3 trial groupsSponsors and collaborators
University of Oxford
Lead sponsor
University College, London
Collaborator
Source ClinicalTrials.gov